FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915660019> ?p ?o ?g. }

• W2915660019 endingPage "265" @default.
• W2915660019 startingPage "260" @default.
• W2915660019 abstract "Lung cancer causes the highest number of cancer-related deaths worldwide. Resistance to therapy is a major clinical issue contributing to the poor prognosis of lung cancer. In recent years, targeted therapy has become a concept where subgroups of non-small cell lung cancer (NSCLC) with genetically altered receptor tyrosine kinases are targeted by tyrosine kinase inhibitors (TKIs). One such subgroup harbors a gene fusion of echinoderm microtubule-associated protein-like 4 (EML4) with anaplastic lymphoma kinase (ALK). Although most NSCLC patients with EML4-ALK fusions initially respond to ALK TKI-therapy they eventually develop resistance. While ALK kinase domain mutations contribute to ALK TKI-refractoriness, they are only present in a fraction of all ALK TKI-resistant tumors. In this study we sought to explore a possible involvement of microRNAs (miRNAs) in conferring resistance to ALK TKIs in ALK TKI-refractory NSCLC cell lines. We subjected our ALK TKI-refractory cancer cells along with parental cancer cells to systematic miRNA expression arrays. Furthermore, ALK TKI-refractory cancer cells were exposed to a synthetic miRNA inhibitory Locked Nucleic Acid (LNA)-library in the presence of ALK TKIs Crizotinib or Lorlatinib. The outcome of the combined approaches uncovered miR-100-5p to confer resistance to Crizotinib and Lorlatinib in EML4-ALK NSCLC cells and to be a potential therapeutic target in drug resistance." @default.
• W2915660019 created "2019-03-02" @default.
• W2915660019 creator A5005273058 @default.
• W2915660019 creator A5008493801 @default.
• W2915660019 creator A5013066091 @default.
• W2915660019 creator A5018148458 @default.
• W2915660019 creator A5020069243 @default.
• W2915660019 creator A5022983271 @default.
• W2915660019 creator A5049703961 @default.
• W2915660019 creator A5056073227 @default.
• W2915660019 creator A5071052597 @default.
• W2915660019 creator A5077630975 @default.
• W2915660019 creator A5087206674 @default.
• W2915660019 date "2019-04-01" @default.
• W2915660019 modified "2023-10-17" @default.
• W2915660019 title "miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC" @default.
• W2915660019 cites W1909496986 @default.
• W2915660019 cites W1972760716 @default.
• W2915660019 cites W2000545640 @default.
• W2915660019 cites W2036748804 @default.
• W2915660019 cites W2051613731 @default.
• W2915660019 cites W2051665334 @default.
• W2915660019 cites W2096156234 @default.
• W2915660019 cites W2113327188 @default.
• W2915660019 cites W2130979840 @default.
• W2915660019 cites W2140333474 @default.
• W2915660019 cites W2148686659 @default.
• W2915660019 cites W2162674813 @default.
• W2915660019 cites W2168106545 @default.
• W2915660019 cites W2202341402 @default.
• W2915660019 cites W2213318739 @default.
• W2915660019 cites W2299266038 @default.
• W2915660019 cites W2482427906 @default.
• W2915660019 cites W2529194187 @default.
• W2915660019 cites W2534390269 @default.
• W2915660019 cites W2588025094 @default.
• W2915660019 cites W2605523966 @default.
• W2915660019 cites W2765224886 @default.
• W2915660019 cites W2885305111 @default.
• W2915660019 cites W4246964423 @default.
• W2915660019 doi "https://doi.org/10.1016/j.bbrc.2019.02.016" @default.
• W2915660019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30791979" @default.
• W2915660019 hasPublicationYear "2019" @default.
• W2915660019 type Work @default.
• W2915660019 sameAs 2915660019 @default.
• W2915660019 citedByCount "15" @default.
• W2915660019 countsByYear W29156600192019 @default.
• W2915660019 countsByYear W29156600192020 @default.
• W2915660019 countsByYear W29156600192021 @default.
• W2915660019 countsByYear W29156600192022 @default.
• W2915660019 countsByYear W29156600192023 @default.
• W2915660019 crossrefType "journal-article" @default.
• W2915660019 hasAuthorship W2915660019A5005273058 @default.
• W2915660019 hasAuthorship W2915660019A5008493801 @default.
• W2915660019 hasAuthorship W2915660019A5013066091 @default.
• W2915660019 hasAuthorship W2915660019A5018148458 @default.
• W2915660019 hasAuthorship W2915660019A5020069243 @default.
• W2915660019 hasAuthorship W2915660019A5022983271 @default.
• W2915660019 hasAuthorship W2915660019A5049703961 @default.
• W2915660019 hasAuthorship W2915660019A5056073227 @default.
• W2915660019 hasAuthorship W2915660019A5071052597 @default.
• W2915660019 hasAuthorship W2915660019A5077630975 @default.
• W2915660019 hasAuthorship W2915660019A5087206674 @default.
• W2915660019 hasConcept C117643217 @default.
• W2915660019 hasConcept C121608353 @default.
• W2915660019 hasConcept C126322002 @default.
• W2915660019 hasConcept C170493617 @default.
• W2915660019 hasConcept C2776232967 @default.
• W2915660019 hasConcept C2776256026 @default.
• W2915660019 hasConcept C2778347629 @default.
• W2915660019 hasConcept C2778820342 @default.
• W2915660019 hasConcept C2779422266 @default.
• W2915660019 hasConcept C2781230642 @default.
• W2915660019 hasConcept C42362537 @default.
• W2915660019 hasConcept C502942594 @default.
• W2915660019 hasConcept C71924100 @default.
• W2915660019 hasConcept C86803240 @default.
• W2915660019 hasConceptScore W2915660019C117643217 @default.
• W2915660019 hasConceptScore W2915660019C121608353 @default.
• W2915660019 hasConceptScore W2915660019C126322002 @default.
• W2915660019 hasConceptScore W2915660019C170493617 @default.
• W2915660019 hasConceptScore W2915660019C2776232967 @default.
• W2915660019 hasConceptScore W2915660019C2776256026 @default.
• W2915660019 hasConceptScore W2915660019C2778347629 @default.
• W2915660019 hasConceptScore W2915660019C2778820342 @default.
• W2915660019 hasConceptScore W2915660019C2779422266 @default.
• W2915660019 hasConceptScore W2915660019C2781230642 @default.
• W2915660019 hasConceptScore W2915660019C42362537 @default.
• W2915660019 hasConceptScore W2915660019C502942594 @default.
• W2915660019 hasConceptScore W2915660019C71924100 @default.
• W2915660019 hasConceptScore W2915660019C86803240 @default.
• W2915660019 hasFunder F4320309792 @default.
• W2915660019 hasFunder F4320309793 @default.
• W2915660019 hasFunder F4320321033 @default.
• W2915660019 hasFunder F4320322315 @default.
• W2915660019 hasFunder F4320322570 @default.
• W2915660019 hasFunder F4320322833 @default.
• W2915660019 hasIssue "2" @default.

• next